The human immunodeficiency virus (HIV) therapy market is dynamic and growing. With the launches of many effective antiretroviral therapies (ARTs), such as Gilead’s Biktarvy and ViiV’s Dovato,…
The HIV therapy market is crowded with many approved antiretroviral therapies (ARVs). Growth in this market is being driven by the increasing acceptance of new, high-priced ARVs, particularly the…
Pre-exposure prophylaxis (PrEP) is a key prevention strategy for ending the human immunodeficiency virus (HIV) epidemic. The FDA’s approval of Gilead’s Truvada in 2012 and Descovy in 2019…
Epidemiology Data Slicer
China has a high disease burden of human immunodeficiency virus (HIV), but patients are well managed by different classes of antiretroviral therapies (ARTs), including single-tablet regimens (e.g…
HIV is a deadly viral infection that impairs cells of the immune system and progressively destroys the body’s ability to fight infections. Availability of multiple therapeutic agents for…
Clarivate Epidemiology’s coverage of human immunodeficiency virus (HIV) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed…
DRG Epidemiology’s coverage of human immunodeficiency virus (HIV) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence…
DRG Epidemiology’s coverage of human immunodeficiency virus (HIV) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence…
Clarivate Epidemiology’s coverage of human immunodeficiency virus (HIV) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed…
Clarivate Epidemiology’s coverage of human immunodeficiency virus (HIV) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed…
Clarivate Epidemiology’s coverage of human immunodeficiency virus (HIV) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed…